Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 18/20 | 0.65 |
| ▸ | DDB1 | Q16531 | 17/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | GSPT1 | P15170 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25091748 | 0.95 | CRBN (0.60) | CRBNDDB1POLBGSPT1 | |
| SCHEMBL24754171 | 0.88 | CRBN (0.66) | CRBNDDB1POLBGSPT1 | |
| SCHEMBL26641290 | 0.85 | CRBN (0.66) | CRBNDDB1POLBGSPT1 | |
| SCHEMBL26641358 | 0.84 | CRBN (0.64) | CRBNDDB1POLBGSPT1 | |
| SCHEMBL24206842 | 0.83 | CRBN (0.62) | CRBNDDB1POLBGSPT1 | |
| SCHEMBL26641306 | 0.83 | CRBN (0.62) | CRBNDDB1POLBGSPT1 | |
| SCHEMBL24548362 | 0.82 | CRBN (0.63) | CRBNDDB1POLB | |
| SCHEMBL7828080 | 0.81 | CRBN (0.70) | CRBNDDB1POLBGSPT1 | |
| SCHEMBL25026923 | 0.81 | CRBN (0.70) | CRBNDDB1POLBGSPT1 | |
| SCHEMBL25026926 | 0.81 | CRBN (0.70) | CRBNDDB1POLBGSPT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4328219-A1 | SOS1 DEGRADING AGENT AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Shanghai Leadingtac Pharmaceutical Co. Ltd. (CN) | 2024-02-28 | — | — | EP | disclosed |
| US-20240018162-A1 | BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF | NURIX THERAPEUTICS, INC. | 2024-01-18 | — | — | US | disclosed |
| US-20230322761-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEONE MEDICINES I GMBH (CH) | 2023-10-12 | — | — | US | disclosed |
| US-20230242541-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | UPPTHERA, INC. (KR) | 2023-08-03 | — | — | US | disclosed |
| US-20230233692-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF RET | C4 THERAPEUTICS, INC. (US) | 2023-07-27 | — | — | US | disclosed |
| WO-2023098656-A1 | COMPOUNDS FOR THE DEGRADATION OF EGFR KINASE | BEIGENE, LTD. (GB) | 2023-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322761-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BTK, CBL, LYN | CRBN 84/4885DDB1 462/4885POLB 3037/4885 |
| US-20230242541-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | PLK1, BUB1B, BUB1 | CRBN 2136/4885DDB1 132/4885POLB 874/4885 |
| US-20230233692-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF RET | RET, HRAS, RBX1 | CRBN 10/4885DDB1 397/4885POLB 3875/4885 |
| US-20240018162-A1 | BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF | TTK, HIPK1, CLK1 | CRBN 218/4885DDB1 675/4885POLB 1715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.